Several allosteric inhibitors of SHP2 are being pursued as cancer therapies, and many of these molecules bind between the C-SH2 and PTP domains to stabilize the auto-inhibited state (Figure 7A)90,91. The gene discussed is PTPN11; the disease is cancer.